KRTX / Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter. more_horizontal

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock h more_horizontal

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative more_horizontal

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studi more_horizontal

Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the trea more_horizontal

Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizop more_horizontal

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Directo more_horizontal

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales. more_horizontal